FDA Awards Orphan Drug and Rare Pediatric Disease Designations to the World’s First Cas13X RNA Base-editing Therapy for the Treatment of Congenital Hearing Loss

HuidaGene's Sixteen Abstracts Highlight the Strength of the Pipeline and Platform to Advance Genetic Medicines at the 2024 ASGCT Annual Meeting

HuidaGene Receives Orphan Drug Designation from FDA for HG302 for the Potential Treatment of Duchenne Muscular Dystrophy after Receiving Rare Pediatric Drug Designation

HuidaGene Announces Rare Pediatric Drug Designation Granted to HG302, A Novel CRISPR DNA-editing Therapy, for the Treatment of Duchenne Muscular Dystrophy

HuidaGene Therapeutics to Attend BIO-Europe Fall Conference in Munich for Actively Expanding Global Collaboration

HuidaGene Therapeutics Announces First Patient Dosed in Multnational Phase 1/2 Trial of HG004 for Inherited Blindness

U.S. FDA Awards Both Rare Pediatric Disease and Orphan Drug Designations to HG204, a CRISPR RNA-editing Therapy, for the Treatment of MECP2 Duplication Syndrome

HuidaGene Therapeutics Announces Last Patient Dosed in Clinical Trial of HG004 for the Treatment of Leber Congenital Amaurosis

HuidaGene Therapeutics Announces 13 Presentations at the Upcoming European Society of Gene and Cell Therapy (ESGCT) Annual Meeting